Athersys CEO elected chair of regenerative medicine trade group
Athersys Inc. CEO Gil Van Bokkelen has been elected chairman of the The Alliance for Regenerative Medicine.
Athersys CEO downplays effect of lorcaserin decision
An FDA panel's decision to reject the obesity drug lorcaserin shouldn't affect Athersys Inc.'s (NASDAQ: ATHX) development of a similar drug, the Cleveland-based company's chief executive said.
presented by
Why Workflow Chaos Is Undermining Care – and What Providers Can Do About It.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Athersys looking for commercial partners to advance stem cell, drug therapies
Biopharmaceutical company Athersys Inc. is looking for commercial partners to help it develop and test its stem cell and drug therapies aimed at treating a variety of health problems. The company reported a narrowed loss and lower revenues in the second quarter from a year ago.